Drug reference
ado-trastuzumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Anti Neoplastics)
Mechanism of action
HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative), Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation.
Common side effects
- Constipation
- Fatigue
- Nausea
- Thrombocytopenia
- Hemorrhage
- Musculoskeletal pain
- AST/ALT increased
Related conditions
Frequently asked questions
What drug class is ado-trastuzumab?
ado-trastuzumab belongs to: Oncology.
How does ado-trastuzumab work?
HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative), Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation.
What are the common side effects of ado-trastuzumab?
Constipation, Fatigue, Nausea, Thrombocytopenia, Hemorrhage, Musculoskeletal pain, AST/ALT increased
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.